Market Overview The US anti-fungal treatment market is advancing as mucormycosis management requires urgent antifungal intervention across American tertiary care centers. The US Anti-Fungal Treatment Market is projected to grow through 2030, driven by increasing diabetes-related rhino-orbital infections, growing hematologic malignancy-associated pulmonary disease, rising deferoxamine-related...